Gilead Sciences, Inc. (ETR:GIS)
Germany · Delayed Price · Currency is EUR | Market Cap | 129.17B |
| Revenue (ttm) | 24.79B |
| Net Income (ttm) | 6.91B |
| Shares Out | n/a |
| EPS (ttm) | 5.47 |
| PE Ratio | 18.69 |
| Forward PE | 14.05 |
| Dividend | 2.76 (2.65%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 61 |
| Average Volume | 883 |
| Open | 103.06 |
| Previous Close | 103.98 |
| Day's Range | 102.66 - 103.06 |
| 52-Week Range | 82.04 - 111.84 |
| Beta | 0.35 |
| RSI | 46.05 |
| Earnings Date | Feb 10, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate
DALLAS--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”) today announced a research collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) (“Gilead”) to evaluate OncoNano's ON-BOARD™ encapsulati...
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior day's close.
Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 15 years by 1.5% on an annualized basis producing an average annual return of 13.34%. Currently, Gilead Sciences has a market ...
XLV, ABT, AMGN, GILD: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
What's Driving the Market Sentiment Around Gilead Sciences Inc?
Gilead Sciences Inc's (NYSE: GILD) short interest as a percent of float has risen 17.45% since its last report. According to exchange reported data, there are now 21.65 million shares sold short , wh...
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.
December 2028 Options Now Available For Gilead Sciences (GILD)
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the December 2028 expiration. One of the key inputs that goes into the price an option buyer is willing to p...
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million
Gilead agreed to acquire Repare's RP-3467 ... Full story available on Benzinga.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset
Gilead to buy Repare Thera’s cancer candidate for up to $30M
Repare Therapeutics (RPTX) stock surges as the company agrees to sell its cancer drug RP-3467 to Gilead (GILD) for up to $30M. Read more here,
Noteworthy ETF Inflows: JQUA, GILD, CB, ADP
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan US Quality Factor ETF (Symbol: JQUA) where we have detected a...
GILD Exercises Option to License Assembly Bio's Herpes Programs
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning ...
Gilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con...
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes
Gilead Sciences, Inc. (NASDAQ: GILD) and Assembly Biosciences, Inc. (NASDAQ: ASMB) announced on Monday that Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simp...
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Programs
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Programs
Gilead exercises license for Assembly Biosciences herpes programs
Assembly Biosciences (ASMB) Gains Momentum with Gilead Licensing Deal
Assembly Biosciences (ASMB) Gains Momentum with Gilead Licensing Deal
Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs
(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase inhibi...
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus ...
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combine...
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...